here is our detailed schematic!

Stand up for science buffalo!

Excellent presentations yesterday at the Translational Research Cancer Centers Consortium annual meeting. Congratulations to everyone for excellent talks! #TRCCC25

This work also could not have happened without Amber McKenery in the Ebos Lab, who drove this project in the final years. Thank you, Amber!

This work was the result of years of dedicated work and sacrifice by Yuhao (Tom) Shi, a talented MD/PhD @ubuffalo.bsky.social student in the Ebos Lab who received F30 NIH Funding from the NCI and is now doing his residency in NYU's #radonc program. Congratulations Tom!

We found that the interferon-regulated secretory machinery in tumor cells is ‘rewired’ after acquired resistance to PD-L1 inhibition, altering the immune microenvironment and decreasing the tumor-killing ability of T cells. @roswellpark.bsky.social #oncosky #medsky #cancerresearch #drugresistance

Able to capture the esteemed @mikefeigin.bsky.social and Ethan Abel discussing their next big discovery

Excellent retreat today showcasing all of the amazing science a Roswell Park Comprehensive Cancer Center.

Our study identifies an unexpected 'senomimetic' side-effect of TKIs more typically associated with blocking angiogenesis. VEGFR TKIs can modulate nearby immune cell activity by promoting IFN/STING signaling, which improves response with PD-L1 inhibitors.

Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase–relevant subgroup with therapeutic prospects

insight.jci.org/articles/6106